Evidera, Bethesda, MD. RATIONALE: Chronic cough (CC) is a condition resulting in negative impacts on QoL. The LCQ is a cough-specific QoL measure which has a Total, Physical, Psychological, and Social domain scores. The objective was to define minimal clinically important differences (MCID) for the LCQ. METHODS: Pooled data from a Phase 2 RCT of an investigational treatment for CC were analyzed. Participants were non-smokers, had refractory/unexplained CC for > _1yr, and baseline cough severity VAS > _40mm. LCQ (Baseline, Week4) and Patient Global Impression of Change (PGIC; Week4) data were analyzed. MCIDs were defined using distribution-based (MCID-D; ½ standard deviation and standard error of measurement) and anchor-based (MCID-A; receiver operating characteristic curves [ROC] and PGIC) analyses. RESULTS: Analyses (n5253; mean age 60.2; 76% female) resulted in MCID-D estimates of 1.5-point increases for LCQ Total and 0.42-0.85-point increases for domain scores. MCID-A/ROC analyses indicated that mean increases > _1.7 points for LCQ Total and > _ 0.8, 0.9, and 0.8 points for Physical, Psychological, and Social domain scores, respectively, had the best sensitivity/specificity for predicting Week4 PGIC responses of ''somewhat improved,'' ''improved,'' or ''very much improved.'' Among participants with Week4 LCQ Total score increases > _2 points, 93.7% responded as at least ''somewhat improved'' (58.3% ''improved'' or ''very much improved''; 35.4% ''somewhat improved''). CONCLUSIONS: These results provide guidance on the degree of change in LCQ scores that can be considered clinically meaningful to help guide treatment decisions and drug development. Specifically, clinicians may consider a 1.5-to 2-point increase in the LCQ Total score as a clinically meaningful improvement for individual patients. 
RESULTS:
The study identified 605,614 total asthma patients; 92,027 (15.2%) with MSA, and 37,220 (6.1%) with MSA and Ex/R. Compared with non-MSA patients, MSA patients incurred greater total ($15,244 vs $10,860) and asthma-related ($3,853 vs $1,670) health care costs during the 12-month follow-up period. MSA patients with Ex/R incurred greater total health care costs than MSA patients without Ex/R ($18,233 vs $13,215), and greater asthma-related pharmacy expenditures ($2,160 vs $327). CONCLUSIONS: Cost differences between MSA and non-MSA patients were primarily driven by the sub-group of MSA patients with Ex/R, partly because of asthma-related pharmacy expenditures. Future research exploring approaches to minimize and better control exacerbations, which may reduce the economic burden of asthma, is warranted.
